Alexia Iasonos | Algorithm Development | Best Researcher Award

Published on by Research Data Analysis

Dr. Alexia Iasonos | Algorithm Development | Best Researcher Award

Memorial Sloan-Kettering Cancer Center | United States

Dr. Alexia E. Iasonos is a recognized expert in biostatistics, currently a Member at Memorial Sloan Kettering Cancer Center where she serves as Director of Clinical Research Development. She earned her B.S. in Mathematics & Statistics from the University of Cyprus (1992-96), followed by an M.S. in Biometry & Statistics and a Ph.D. in Biometry & Statistics from SUNY Albany (awarded in 1998 and 2002 respectively). Her professional trajectory includes roles in academic statistics, pharmaceutical industry, and extensive hospital-affiliated clinical trial biostatistics. Her methodological research focuses on design and analysis of clinical trials, especially Bayesian adaptive Phase I and II designs, dose-finding methods, dose-expansion cohort development, predictive modeling and nomograms, biomarker evaluation and endpoints, particularly in gynecologic oncology. Her work has been instrumental in improving early drug development processes. According to AD Scientific Index, her h-index is 52, with over 10,779 total citations. She is an elected Fellow of the Society of Clinical Trials, deputy editor of Journal of Clinical Oncology, member/chair in several protocol and monitoring committees. Among her awards are those tied to leadership in early-phase trial methodology and contributions to cancer biostatistics. In conclusion, Dr. Iasonos continues to make high impact contributions in biostatistics and oncology by combining rigorous methodology with translational collaboration.

Profile : Scopus

Featured Publications

Iasonos, A. (2024). Evaluation of early phase dose finding algorithms in heterogeneous populations. Journal of Statistical Planning and Inference.

Iasonos, A. (2023). Controlled amplification in oncology dose-finding trials. Contemporary Clinical Trials.

Iasonos, A. (2022). Stopping rules for phase I clinical trials with dose expansion cohorts. Statistical Methods in Medical Research.

Iasonos, A. (2021). Controlled backfill in oncology dose-finding trials. Contemporary Clinical Trials.

Iasonos, A. (2021). Phase I clinical trials in adoptive T-cell therapies. Journal of the Royal Statistical Society: Series C (Applied Statistics).

Vicente Vanaclocha | Neuroscience Data Analysis | Best Scholar Award

Published on by Research Data Analysis

Prof. Dr. Vicente Vanaclocha | Neuroscience Data Analysis | Best Scholar Award

Universidad de Valencia | Spain

Prof. Dr. Vicente Vanaclocha is a distinguished neurosurgeon and academic recognized for his outstanding contributions to medical science, education, and clinical innovation. He obtained his Licenciatura in Medicine (1981) and completed his PhD in Neurosciences (1988) at the Universitat de València, where his doctoral research focused on experimental studies of ionizing radiation responses in epileptic foci. His academic record includes specialized training in Neurocirugía, earning the European Neurosurgery Title in 1994, and postgraduate degrees in healthcare management and hospital administration. With decades of teaching experience across prestigious institutions such as Universitat de València, Universidad Católica de Valencia, Universidad de Navarra, and Universidad Miguel Hernández de Elche, he has trained medical students, residents, and international fellows in advanced neurosurgical techniques. He has directed research grants, mentored doctoral candidates, and contributed significantly to knowledge in neuro-oncology, vascular neurosurgery, and innovative surgical procedures. Recipient of multiple academic and clinical recognitions, he continues to combine clinical excellence with research and teaching, advancing neurosurgery and medical education for future generations.

Profiles : Orcid | sciprofiles

Featured Publications

Vanaclocha, A., Vanaclocha, V., Atienza, C., Jordá-Gomez, P., Peñuelas, A., & Gomez-Lopez, D. (2025). Facet Joint Loading After Kevlar-Reinforced Disc Replacement vs. Lumbar Fusion. A cadaveric model study. Journal of Clinical Orthopaedics and Trauma.

Vanaclocha, A., Vanaclocha, V., Atienza, C. M., Jordá-Gómez, P., Primo-Capella, V., Blasco, J. R., Portolés, L., Saiz-Sapena, N., & Vanaclocha, L. (2025). Effect of Ti6Al4V Alloy Surface and Porosity on Bone Osseointegration: In Vivo Pilot Study in Rabbits. Materials.

Lovera, K., Vanaclocha, V., Atienza, C. M., Vanaclocha, A., Jordá-Gómez, P., Saiz-Sapena, N., & Vanaclocha, L. (2025). Dental Implant with Porous Structure and Anchorage: Design and Bench Testing in a Calf Rib Model Study. Materials.

Vanaclocha, V., Atienza, C., Vanaclocha, A., Peñuelas, A., Gómez-Herrero, J., Pérez-Carrió, F., Diego-Leyda, J. A., Sáiz-Sapena, N., & Vanaclocha, L. (2025). New Subperiosteal Dental Implant Design with Finite Element Analysis and Mechanical Validation: A Design Validation Study. Materials.

Vanaclocha, V., Herrera, J. M., Rivera-Paz, M., Saiz-Sapena, N., & Vanaclocha, L. (2024). Can a single basal cistern urokinase bolus help to prevent subarachnoid hemorrhage consequences? Heliyon.

Weiren Huang | Genomic Data Analytics | Best Researcher Award

Published on by Research Data Analysis

Dr. Weiren Huang | Genomic Data Analytics | Best Researcher Award

Dr. Weiren Huang | Genomic Data Analytics – The First Affiliated Hospital of Shenzhen University, Department of Urology, Shenzhen Institute of Translational Medicine, Shenzhen Second People’s Hospital | China

Dr. Weiren Huang is a pioneering researcher and principal investigator at The First Affiliated Hospital of Shenzhen University, working within the Department of Urology and the Shenzhen Institute of Translational Medicine. Recognized for his significant contributions to synthetic biology and its therapeutic applications in oncology, Dr. Huang has emerged as a national figure in precision gene circuit design and tumor-targeted interventions. As Deputy Director of the Synthetic Biology Committee under the China Medicinal Biotechnology Association and a committee member of several national scientific panels, he continues to drive innovation at the intersection of engineering biology and translational medicine. His work is transforming bladder cancer treatment through personalized, programmable therapeutics that hold promise for clinical implementation.

Professional Profile

ORCID

Education

Dr. Huang earned his Ph.D. in a highly competitive program from Sun Yat-sen University, one of China’s premier research institutions. This rigorous academic foundation enabled him to integrate core knowledge in molecular biology, biomedical engineering, and translational medicine. His doctoral research set the stage for a career focused on genetic control systems and their application in oncology, especially through synthetic biology platforms. His educational background laid a solid groundwork for interdisciplinary research, bringing together urology, gene therapy, and bioengineering in a seamless and impactful way.

Experience

With extensive experience as Principal Investigator in national and regional research programs, Dr. Huang has led critical projects supported by the Ministry of Science and Technology of China, Shenzhen Science and Technology Innovation Commission, and Shenzhen Medical Research Fund. These initiatives address emerging clinical needs using genetic circuitry, tumor organoid modeling, and synthetic therapeutics. His notable leadership includes the National Key R&D Program project focused on microenvironment remodeling via gene circuits, where he directed a team on an ¥18.53 million venture that concluded successfully in 2024. As a research leader, he has managed multidisciplinary teams in high-throughput drug screening, cancer modeling, and cell-factory development, ensuring the translational potential of every scientific outcome.

Research Interest

Dr. Huang’s research interests center on synthetic biology, specifically the design and deployment of gene circuits for bladder cancer therapy. His approach involves integrating programmable gene expression modules with delivery vectors that selectively induce pyroptosis in tumor cells, ensuring minimal off-target effects. Another major focus is the use of tumor organoid chips to create personalized models that can evaluate drug sensitivity and gene circuit performance under near-physiological conditions. His work also touches on tumor microenvironment remodeling, examining how synthetic control systems can modulate immune responses and cellular signaling to enhance therapeutic outcomes. His unique angle lies in the development of cell factories and controllable gene expression systems that bridge lab innovation and clinical feasibility.

Awards

Dr. Huang has received significant recognition for his scientific contributions, including the prestigious Chinese Medical Science and Technology Award. He is also a recipient of the Guangdong Provincial Special Support Program for Distinguished Talents, placing him among the Top 100 Scholars of Guangdong. These accolades reflect not only his leadership in synthetic biology but also his broader influence on China’s biomedical innovation ecosystem. His ability to translate benchside discoveries into actionable therapies has earned him a reputation as a transformative scientist and clinician-researcher.

Publications

BCG therapy in bladder cancer and its tumor microenvironment interactions

Authors: Ni Jian, Lei Yu, Lijuan Ma, Binbin Zheng, Weiren Huang, Christopher Staley, Aaron Miller
Journal: Clinical Microbiology Reviews
Year: 2025

CD133⁺PD-L1⁺ cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in melanoma

Authors: Jiaojiao Xu, Zhe Li, Qinli Tong, Sihang Zhang, Jianchen Fang, Aihua Wu, Guoguang Wei, Chen Zhang, Sheng Yu, Binbin Zheng, et al.
Journal: Nature Communications
Year: 2025

Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules

Authors: Ziqiang Wang, Kun Li, Wei Chen, Xiaoxia Wang, Yikun Huang, Weiming Wang, Wanjun Wu, Zhiming Cai, Weiren Huang
Journal: Cellular and Molecular Life Sciences
Year: 2020